rat pnp

Forodesine (BCX-1777) is an orally active and potent purine nucleoside phosphorylase (PNP) inhibitor, a new purine nucleoside analog, inhibitor of human lymphocyte proliferation, induces apoptosis in leukemic cells by increasing dGTP levels, and may be useful in the study of cutaneous T-cell lymphomas.

Peldesine (BCX 34) is an effective, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase. Peldesine inhibits T-cell proliferation with an IC50 of 800 nM. Peldesine can be used in research on cutaneous T-cell lymphoma, psoriasis and HIV infection.

Forodesine hydrochloride (BCX-1777 hydrochloride), a potent inhibitor of human lymphocyte proliferation, effectively induces apoptosis in leukemic cells by elevating dGTP levels. This compound is an orally active, highly potent purine nucleoside phosphorylase (PNP) inhibitor, demonstrating IC50 values between 0.48 to 1.57 nM across human, mouse, rat, monkey, and dog PNP.

Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase (PNP), with IC50 values of 36 nM, 5 nM, and 32 nM against human, rat, and mouse red blood cell (RBC) PNP, respectively. Additionally, it inhibits T-cell proliferation with an IC50 of 800 nM, showing promise for research into cutaneous T-cell lymphoma, psoriasis, and HIV infection [1] [2] [3] [4].